The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.
An increasingly important role for the ErbB3 receptor in the genesis and progression of breast cancer is emerging. ErbB3 is frequently overexpressed in breast cancer and coexpression of ErbB2/3 is a poor prognostic indicator. ErbB3 has also been implicated in the development of resistance to antiestrogens such as tamoxifen and ErbB tyrosine kinase inhibitors such as gefitinib. Persistent activation of the AKT pathway has been postulated to contribute to ErbB3-mediated resistance to these therapies. This activation may be due in part to the inappropriate production of the ErbB3 ligand heregulin. ErbB3 binding proteins, which negatively regulate ErbB3 protein levels and the ability of ErbB3 to transmit proliferative signals, also contribute to breast cancer progression and treatment resistance. These proteins include the intracellular RING finger E3 ubiquitin ligase Nrdp1 and the leucine-rich protein LRIG-1 that mediate receptor degradation. Ebp1, another ErbB3 binding protein, suppresses HRG driven breast cancer cell growth and contributes to tamoxifen sensitivity. These studies point to the importance of the evaluation of protein levels and functional activity of ErbB3 and its binding proteins in breast cancer prognosis and prediction of clinical response to treatment.
Hamburger
Anne W
AW
Greenebaum Cancer Center and Department of Pathology, University of Maryland, Baltimore, BRB 9-029, 655 W. Baltimore Street, Baltimore, MD 21201, USA. ahamburg@som.umaryland.edu
D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism* / Q000503:physiopathology; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008562:Membrane Glycoproteins / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology; D016601:RNA-Binding Proteins / Q000378:metabolism; D020893:Receptor, ErbB-3 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D013629:Tamoxifen / Q000494:pharmacology; D044767:Ubiquitin-Protein Ligases / Q000378:metabolism
D048868:Adaptor Proteins, Signal Transducing; D004965:Estrogen Antagonists; C484445:LRIG1 protein, human; D008562:Membrane Glycoproteins; C101633:PA2G4 protein, human; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D016601:RNA-Binding Proteins; D013629:Tamoxifen; C452580:RNF41 protein, human; D044767:Ubiquitin-Protein Ligases; D020893:Receptor, ErbB-3; D000077156:Gefitinib